Loading stock data…
ORKA
$62.58-5.83 (-8.52%)
Market ClosedLast close May 1
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Oruka Therapeutics, Inc. in the Healthcare sector is trading at $62.58. The stock is currently 31% below its 52-week high of $91.00, remaining 104.1% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why ORKA maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$62.58
Potential Upside
5%
Whystock Fair Value$65.71
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$137.08+119.1%
Range$70.00 – $200.00
Fundamentals
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.48%
Volume
Today's trading volume
3.94M
Recent News
Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001
Oruka Therapeutics (NASDAQ:ORKA) is one of the small-cap stocks that are on fire right now. On April 27, Oruka Therapeutics announced positive interim results from its EVERLAST-A Phase 2a trial for ORKA-001, a long-acting monoclonal antibody targeting moderate-to-severe plaque psoriasis. The study met its primary endpoint, with 63.5% of patients achieving complete skin clearance (PASI […]
Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis Dosing
Oruka Therapeutics (NASDAQ:ORKA) reported 16-week interim results from EVERLAST-A, a double-blind, placebo-controlled phase II study evaluating ORKA-001, the company’s extended half-life IL-23/p19 monoclonal antibody for moderate-to-severe plaque psoriasis. Management highlighted what it described a
Oruka Therapeutics (ORKA) Hits Record High on Stellar Clinical Trial Result
Oruka Therapeutics Inc. (NASDAQ:ORKA) is one of the 10 Stocks Racking Up Monster Gains. Oruka Therapeutics soared to a new record high on Monday, as investors positioned portfolios following positive results from the clinical study of its psoriasis treatment candidate, ORKA-001. In an updated report, Oruka Therapeutics Inc. (NASDAQ:ORKA) said that 40 of the 63 […]
How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise
Nearly two-thirds of patients who received Oruka Therapeutics' experimental psoriasis treatment had completely clear skin after 16 weeks.
Oruka Therapeutics psoriasis drug clears skin in 64% of patients
ORKA-001 also met secondary endpoints at 16 weeks, and updated data support the potential for once-yearly dosing